1.ABO Blood Group Incompatible Living Donor Kidney Transplantation without Splenectomy.
Jin Min KONG ; Dong Ryul LEE ; Joon Heun JEONG ; Jae Ho CHOI ; Jung Oh LEE ; Wha Rhim LEE ; Byung Chang KIM
The Journal of the Korean Society for Transplantation 2009;23(1):71-76
BACKGROUND: Serious organ shortage necessitates ABO incompatible (ABOi) kidney transplantation (KT). Recent reports utilizing rituximab instead of splenectomy and tacrolimus (FK)-based triple immunosuppressants showed excellent graft outcome. METHODS AND RESULTS: Thirteen cases of ABOi living donor KT have been performed since Feb. 2007 in our center. Donor and recipient blood group was B to O (n=5), A1 to O (2), AB to B (2), AB to A1 (1), A1 to B (2) and B to A1 (1). Rituximab was given at 4 weeks before transplantation. Plasmapheresis (PP) was initiated at 7~14 days before transplantation with concurrent immunosuppressants. The number of pretransplant PP was 5.7+/-1.4. Posttransplant PP was also performed in 6 patients with higher initial titer of ABO antibody (IgG > or =256; n=2), rapidly rising antibody titer during the critical period of 2 weeks posttransplantation (n=2), or increase in serum creatinine during the critical period while awaiting pathology report of graft biopsy (n=2). Mean number of posttransplant PP in these 6 patients was 2.2+/-1.3. Median IgG anti-ABO antibody titer before precondition, at transplantation, at 2 weeks and at 6 months was 64 (8~512), 2 (1~8), 2 (1~16) and 6 (1~16), respectively. IgM titer at corresponding time point was 16 (2~128). 1 (1~1), 1 (1~2) and 1.5 (1~4), respectively. Median follow up was 8 (5~27) months. No patient or graft was lost. No patient developed acute humoral rejection. Graft function remained stable with latest serum creatinine 1.2+/-0.3 mg/dl. CONCLUSIONS: ABOi living donor KT without splenectomy can be safely performed with the use of current preconditioning and immunosuppressive regimen, and is therefore a valuable option for expanding donor pool and should be actively performed in Korea.
Antibodies, Monoclonal, Murine-Derived
;
Biopsy
;
Creatinine
;
Critical Period (Psychology)
;
Follow-Up Studies
;
Humans
;
Immunoglobulin G
;
Immunoglobulin M
;
Immunosuppressive Agents
;
Kidney
;
Kidney Transplantation
;
Living Donors
;
Plasmapheresis
;
Rituximab
;
Rejection (Psychology)
;
Splenectomy
;
Tacrolimus
;
Tissue Donors
;
Transplants